Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 4/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25286745 | 0.91 | ALDH1A1 (0.56) | ALDH1A1SMN1; SMN2TSHRLMNAHSD17B10 | |
| SCHEMBL28655610 | 0.86 | ALDH1A1 (0.59) | ALDH1A1SMN1; SMN2TSHRLMNAACHE | |
| SCHEMBL5709898 | 0.86 | ALDH1A1 (0.62) | ALDH1A1SMN1; SMN2TSHRRECQLLMNA | |
| SCHEMBL22588740 | 0.85 | TSHR (0.35) | ALDH1A1SMN1; SMN2TSHRRECQLLMNA | |
| SCHEMBL29991209 | 0.84 | ALDH1A1 (0.63) | ALDH1A1SMN1; SMN2TSHRLMNAACHE | |
| SCHEMBL23829960 | 0.84 | ALDH1A1 (0.63) | ALDH1A1SMN1; SMN2TSHRLMNAACHE | |
| SCHEMBL28340776 | 0.84 | ALDH1A1 (0.63) | ALDH1A1SMN1; SMN2TSHRLMNAACHE | |
| SCHEMBL18286735 | 0.81 | ALDH1A1 (0.52) | ALDH1A1SMN1; SMN2TSHRRECQLNPSR1 | |
| SCHEMBL25282552 | 0.80 | ALDH1A1 (0.48) | ALDH1A1SMN1; SMN2TSHRLMNAHTT | |
| SCHEMBL6891204 | 0.79 | ALDH1A1 (0.54) | ALDH1A1SMN1; SMN2TSHRRECQLLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108350062-B | Targeted protein degradation to attenuate adverse inflammatory responses associated with adoptive T cell therapy | 达纳-法伯癌症研究所股份有限公司 | 2022-10-14 | — | — | CN | disclosed |
| CN-111386263-A | Modulation of chimeric antigen receptors | 达纳-法伯癌症研究所有限公司 | 2020-07-07 | — | — | CN | disclosed |
| CN-107257800-B | Method for inducing target protein degradation by bifunctional molecules | 达纳-法伯癌症研究所股份有限公司 | 2020-06-30 | — | — | CN | disclosed |
| CN-110621322-A | Modulatable endogenous protein degradation with heterobifunctional compounds | 达纳-法伯癌症研究所有限公司 | 2019-12-27 | — | — | CN | disclosed |